Neonataldiagnostik-Unternehmen InfanDx AG platziert überzeichnete zweite Tranche der Serie A
15 mars 2022 05h00 HE
|
AKAMPION
Zweite Tranche von ca. EUR 2 Millionen durch starke Investorennachfrage getragenTransaktion mehr als 50% überzeichnetFinanzierung bietet weitere Liquidität für Produktentwicklung – R&D...
InfanDx AG: Clinical Findings from Prospective AAMBI Study Highlight Need for Better Early Detection of Neonatal Brain Injury
10 févr. 2022 04h00 HE
|
AKAMPION
Scientific poster presented at the 13th International Newborn Brain ConferenceData demonstrate the importance of novel and reliable diagnostic markers for the early detection of Hypoxic-Ischemic...
InfanDx AG: Klinische Ergebnisse der prospektiven AAMBI Studie unterstreichen Bedarf an besserer Früherkennung neonataler Hirnschäden
10 févr. 2022 04h00 HE
|
AKAMPION
Präsentation eines wissenschaftlichen Posters auf der 13th International Newborn Brain Conference Daten belegen die Bedeutung neuer und verlässlicher diagnostischer Marker zur Früherkennung von...
Neonatal Diagnostics Company InfanDx AG Establishes Scientific Advisory Board
19 janv. 2022 04h00 HE
|
AKAMPION
Team of seasoned scientific advisors to further guide InfanDx on diagnostic needs and product concepts in neonatal acute and critical careInaugurating meeting focused on positioning of HypoxE® Test in...
Neonataldiagnostik-Unternehmen InfanDx AG etabliert wissenschaftlichen Beirat
19 janv. 2022 04h00 HE
|
AKAMPION
Team erfahrener wissenschaftlicher Experten zur Beratung von InfanDx bei diagnostischem Bedarf und Produktkonzepten in der neonatalen Akut- und IntensivmedizinSchwerpunkte der Eröffnungssitzung:...
Eisbach Bio and MD Anderson announce strategic collaboration to develop medicines targeting epigenetic machinery in oncology
18 janv. 2022 09h00 HE
|
AKAMPION
MUNICH and HOUSTON; January 18, 2022 ― Eisbach Bio GmbH and The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration to jointly discover and develop...
BellaSeno Announces Publication of First-in-Human Data of its Lead Program Senella
07 déc. 2021 04h00 HE
|
AKAMPION
- Successful initial treatment of pectus excavatum patient in Australia - Data published in the European Journal of Plastic Surgery confirms Bellaseno’s novel approach in soft tissue engineering ...
ImmunOs Therapeutics Appoints Steve Coats, PhD, as Chief Development Officer
06 déc. 2021 04h00 HE
|
AKAMPION
- Company adds significant immunotherapy development expertise to its management team- Clinical trial of lead compound IOS-1002 to start in 2022 Schlieren (Zurich Area), Switzerland. – December...
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
15 nov. 2021 03h00 HE
|
AKAMPION
- Promising data presented at Society for Immunotherapy of Cancer 36th Annual Meeting (SITC) - Multi-functional agent targeting three innate immune checkpoint receptors - Potential as monotherapy and...
Curexsys Appoints Christian Eckert as Chief Operating Officer
20 oct. 2021 04h00 HE
|
AKAMPION
- Strengthened management team headed by Jörg Neermann as CEO Goettingen, Germany, October 20, 2021 - Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the...